BEAT-SHOCK Registry
NCT07643610 · Cardiogenic Shock, Myocardial Infarction (MI), Fulminant Myocarditis
RecruitingThis regulation defines the purpose, the operational processes, and the organization of the registry BEAT-SHOCK (Basel Evaluation of Acute Therapy in cardiogenic SHOCK). It describes the requirements for collecting, storing, processing, managing and sharing health-related registry data.
Phase—
TypeObservational
Age18 Years
WhereBasel, Canton of Basel-City, Switzerland
SponsorUniversity Hospital, Basel, Switzerland
▾Tap for detailsClick for full details — eligibility, all locations, contacts Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
NCT00271180 · Arrhythmia, Bradycardia,
Heart Failure RecruitingThe main purpose of the Product Performance Report (formerly referred to as System Longevity Study) is to evaluate long-term performance of Medtronic market-released cardiac rhythm products by analyzing product survival probabilities.
Phase—
TypeObservational
AgeAny
WhereBirmingham, Alabama, United States + 337 more
SponsorMedtronic
▾Tap for detailsClick for full details — eligibility, all locations, contacts Echocardiography in Nursing Home
NCT06445231 · Heart Diseases,
Heart Failure, Heart Valve Diseases
RecruitingThe study seeks to explore the implementation characteristics (acceptability, appropriateness, feasibility, adoption, fidelity, penetration, implementation cost and sustainability) of systematic echocardiography in nursing homes and its impact on rates of heart failure flare-up and unscheduled hospitalization at 12 months among included nursing homes.
PhaseNA
TypeInterventional
Age65 Years
WhereNantes, Loire-Atlantique, France
SponsorNantes University Hospital
▾Tap for detailsClick for full details — eligibility, all locations, contacts TIER-PC is an adaptive model of delivering palliative care that provides the right level of care to the right patients at the right time. It represents an adaption of the Mount Sinai PALLIATIVE CARE AT HOME (PC@H) program, which delivers home-based palliative care. TIER-PC increases the number and intensity of disciplines added to the patient's care team as their symptoms worsen and function declines. In Tier 1, patients who are able to care for themselves and no/mild symptoms receive a community health worker (CHW) trained to elicit illness understanding in a culturally competent way. In Tier 2, for patients with poorer function and mild symptoms, a social worker (SW), trained in serious illness communication, joins the CHW to further elicit patients' goals and prognostic understanding while communicating symptom needs to their primary clinician. In Tier 3, as function decreases and symptoms increase, an advance practice nurse (APN) joins the CHW and SW to manage complex symptoms. Finally, in Tier 4, for those older adults with the poorest function and most complex symptoms, a physician joins the team to ensure that the most complex needs (e.g., end-of-life treatment preferences and multifaceted symptom control) are met. The CHW follows patients longitudinally across all tiers and re-allocates them to the appropriate tier based on their evolving needs.
PhaseNA
TypeInterventional
Age18 Years
WhereAstoria, New York, United States + 4 more
SponsorIcahn School of Medicine at Mount Sinai
▾Tap for detailsClick for full details — eligibility, all locations, contacts Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
RecruitingIt is believed that targeted SERCA2a enzyme replacement in HFrEF patients will correct defective intracellular Ca2+ hemostasis, resulting in improved cardiac contractile function and energetics which will, in turn, translate to improved clinical outcomes. Additionally, it is hypothesized that correcting SERCA2a dysfunction will also improve coronary blood flow through correction of the impaired endothelium-dependent nitric oxide-mediated vasodilatation observed in heart failure.
PhasePhase 1 / Phase 2
TypeInterventional
Age18 Years – 80 Years
WhereSan Diego, California, United States + 4 more
SponsorSardocor Corp.
▾Tap for detailsClick for full details — eligibility, all locations, contacts Mechanisms And Prognosis of Stroke-Heart Syndrome
NCT06954103 · Stroke, Myocardial Injury,
Heart Failure RecruitingThe incidence of stroke-heart syndrome following acute stroke, which encompasses both acute ischemic stroke and acute intracerebral hemorrhage, is notably high and is strongly associated with increased mortality and poor outcomes in stroke patients. However, the underlying mechanisms remain unclear, and there are currently no effective prevention or treatment strategies. This study aims to elucidate the neuro-humoral mechanisms of stroke-heart syndrome through multimodal imaging and multi-omics blood analysis. Additionally, it seeks to observe the progression of stroke-heart syndrome and its impact on functional outcomes, cognitive abilities, and emotional issues post-stroke. The research is expected to uncover novel blood biomarkers and brain network mechanisms associated with stroke-heart syndrome, providing potential targets and theoretical foundations for pharmacological treatments or physical interventions. Furthermore, it aims to establish a risk early-warning system for major cardiovascular complications post-stroke, enabling early identification, early intervention, and integrated brain-heart management to improve clinical outcomes for stroke patients.
Phase—
TypeObservational
Age18 Years
WhereWuhan, Hubei, China
SponsorChensheng Pan
▾Tap for detailsClick for full details — eligibility, all locations, contacts Exercise Lower-body Negative Pressure in Heart Failure With Preserved Ejection Fraction
RecruitingThe heart is a pump that must both fill and empty effectively to move blood; if it cannot move enough, heart failure may ensue. Approximately half of all adults living with heart failure have a form where the heart stiffens, which impairs its ability to fill. This form of heart failure particularly affects females and older adults. When people exercise, extra blood returns to the heart. The healthy heart can easily fill and move this extra blood to the muscles. However, when the heart's ability to fill is impaired, the extra blood can back up and pool in the lungs. Blood pooling in the lungs makes people feel breathless, although the investigators do not fully understand why, and this form of heart failure has a high risk of hospitalization and death, but few effective treatments are available. Exercise is one of the few treatments that works well if enough exercise is performed regularly. However, many people with this form of heart failure can only tolerate a small amount before stopping due to severe breathlessness, which can put them off from exercising regularly. The study's goal is to help these people perform more exercise. The investigators will use a novel form of stationary cycling with a plastic chamber around the lower body that seals at the waist. The chamber can apply suction to the lower body during exercise which will reduce how much extra blood returns and prevent the heart and lungs from being overloaded. Participants will attend 5 visits, including 3 where they will perform a submaximal exercise test for as many minutes as possible with or without light suction. In each of these tests, the investigators will record how long they exercise and ask them to rate how breathless they feel. The investigators will also study their breathing pattern, using a mouthpiece and pressure sensor, and heart function, using ultrasound imaging. This work will help adults living with heart failure exercise more and improve their health, and help researchers understand what causes breathlessness and develop new treatments.
PhaseNA
TypeInterventional
Age40 Years
WhereKelowna, British Columbia, Canada
SponsorUniversity of British Columbia
▾Tap for detailsClick for full details — eligibility, all locations, contacts Midodrine in Heart Failure With Reduced Ejection Fraction With Hypotension
RecruitingThe evidence-based pharmacologic treatments available for patients with heart failure with reduced ejection fraction (HFrEF) has been established over the last few decades of cardiovascular research. These treatments, termed Foundational Guideline-Directed-Medical Therapies (GDMT), prolong patient life, improve patient-reported symptoms, and reduce hospitalizations for heart failure. A direct effect of most medication classes encompassed within GDMT is the reduction in blood pressure due to their mechanisms of action. In addition, as patients with HFrEF become more advanced in their disease, a significant proportion develop hypotension related to pump failure and autonomic dysfunction, amongst other possible mechanisms. As a result, a significant proportion of HFrEF patients are not optimized on GDMT with hypotension as their limiting barrier that would otherwise have served to improve their heart function, heart failure symptoms, and mortality. Currently, there does not exist any evidence-based strategies to address the problem of hypotension in HFrEF patients who are not optimized on GDMT. Midodrine is an alpha-adrenergic agonist (α1-AR) that exerts its effects on peripheral venous and arteriolar vasculature to increase blood pressure. This medication has been used off-label by some clinicians in the hypotensive HFrEF population to increase blood pressure and has been reported to have beneficial effects in improving GDMT utilization as well as increasing left ventricular ejection fraction (LVEF) in published case reports/case series. There does not exist any randomized prospective data on the use of midodrine in the hypotensive HFrEF population. The investigators' objective is to complete the first open-label, randomized control trial of midodrine in the hypotensive HFrEF population to demonstrate feasibility in performing a trial in this patient population and to show efficacy in increasing blood pressure without associated harm. The results of this trial will be used as the foundation and rationale for future studies assessing the impact of midodrine use on GDMT utilization as well as hard cardiovascular outcomes in the hypotensive HFrEF population, including hospitalizations for heart failure and mortality.
PhasePhase 2 / Phase 3
TypeInterventional
Age18 Years
WhereOttawa, Ontario, Canada
SponsorOttawa Heart Institute Research Corporation
▾Tap for detailsClick for full details — eligibility, all locations, contacts Sustaining Home Heart Failure Palliative Care in Rural Appalachia
RecruitingThe aim of this mixed methods randomized controlled trial is to test the integrated nurse-led intervention bundle for family home care management of end-stage heart failure and palliative care in rural Appalachia. This intervention bundle is designed to address rural disparities in access to health care, with the help of the faith-based nurses and local volunteer visiting neighbors.
PhaseNA
TypeInterventional
Age45 Years – 80 Years
WhereMorgantown, West Virginia, United States
SponsorWest Virginia University
▾Tap for detailsClick for full details — eligibility, all locations, contacts Leg Heat Therapy in Heart Failure With Preserved Ejection Fraction
RecruitingThe objective of this pilot study is to establish evidence to support the validity of HT in improving skeletal muscle function and physical capacity of patients with HFpEF. Our central hypothesis is that HT treatment will lead to improvements in skeletal muscle and microvascular function compared to a control intervention. As a result, we anticipate that patients treated with HT will demonstrate improved skeletal muscle microvascular blood flow and oxygenation resulting in enhanced exercise tolerance. To explore this hypothesis, we propose the following specific aim: Explore the effects of home-based HT on exercise tolerance in patients with HFpEF.
PhaseNA
TypeInterventional
Age18 Years
WhereIndianapolis, Indiana, United States + 1 more
SponsorIndiana University
▾Tap for detailsClick for full details — eligibility, all locations, contacts Acute Heart Failure With Reduced Ejection Fraction - COngestion Discharge Evaluation
RecruitingThe AHF-CODE reduced study is a prospective, non-randomized, monocenter study performed in patients with heart failure with reduced ejection fraction admitted for worsening heart failure. The main objective of the AHF-CODE study is to identify congestion markers (clinical, biological and ultrasound) at the end of hospitalization for acute heart failure that are associated with the risk of all cause death or rehospitalization for acute heart failure within 3 months of hospital discharge.
PhaseNA
TypeInterventional
Age18 Years
WhereVandœuvre-lès-Nancy, France
SponsorCentral Hospital, Nancy, France
▾Tap for detailsClick for full details — eligibility, all locations, contacts Longitudinal Validation of CIRC Technologies
NCT07081711 · Cardiovascular Diseases,
Heart Failure, Ischemic Heart Disease
RecruitingCardiovascular disease is the leading cause of death worldwide. Advanced cardiovascular imaging using Magnetic Resonance Imaging (MRI) has proven to be effective in providing gold standard myocardial tissue characterization. Moreover, the intrinsic advantage of MRI's lack of exposure to ionizing radiation is particularly beneficial. At the same time, blood work can be very useful in early detection of certain cardiomyopathy, such as amyloid. However, there is a lack of agreement of on which markers are the most sensitive. This multi-study will allow the unique opportunity to form a more comprehensive understanding for various cardiovascular diseases. The study team has developed novel cardiac MRI techniques that leverages endogenous tissue properties to reveal a milieu of deep tissue phenotypes including myocardial inflammation, fibrosis, metabolism, and microstructural defects. Among these phenotypes, myocardial microstructure has proven to be most sensitive to early myocardial tissue damage and is predictive of myocardial regeneration. In this study, the investigators aim to further study the importance of cardiac microstructure revealed by MRI in patient and healthy population and compare this novel technology with conventional clinical biomarkers.
Phase—
TypeObservational
Age18 Years
WhereCleveland, Ohio, United States
SponsorThe Cleveland Clinic
▾Tap for detailsClick for full details — eligibility, all locations, contacts A Multi-center, National, Open-label, Prospective Study to Evaluate the Performance of the V-Lap™ System
NCT06147336 ·
Heart Failure RecruitingThe objective of this study is to evaluate the safety and performance of the V-LAP System in subjects with New York Heart Association (NYHA) functional class II and III HF, irrespective of left ventricular ejection fraction.
PhaseNA
TypeInterventional
Age22 Years – 88 Years
WhereBoston, Massachusetts, United States
SponsorVectorious Medical Technologies Ltd.
▾Tap for detailsClick for full details — eligibility, all locations, contacts CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
NCT07207811 · Transthyretin Amyloid Cardiomyopathy (ATTR CM)
RecruitingThis study will find out if a new medicine called NNC6019-0001 can help reduce the risk of heart-related death and illness in participants with a condition called transthyretin amyloid cardiomyopathy (ATTR-CM), which affects the heart. Participants will either receive NNC6019-0001 or a placebo (a treatment with no active medicine), and which one they get is decided by chance. Everyone in the study will continue receiving their usual heart treatments as recommended by their doctor.
PhasePhase 3
TypeInterventional
Age18 Years
WherePhoenix, Arizona, United States + 298 more
SponsorNovo Nordisk A/S
▾Tap for detailsClick for full details — eligibility, all locations, contacts Risk-guided Disease Management Plan to Prevent Heart Failure in Patients Treated With Previous Chemotherapy (REDEEM)
NCT04962711 ·
Heart Failure RecruitingThis is a prospective study in which a process of identifying and reducing heart failure (HF) risk will be applied to cancer survivors \>55 years old with chemotherapy \>5 years ago. The overall goal of this study to identify the feasibility and value of risk-guided cardiac rehabilitation (exercise, risk factor modification, and behavioural support) as a component of survivorship care.
PhaseNA
TypeInterventional
Age40 Years – 85 Years
WhereMelbourne, Victoria, Australia
SponsorBaker Heart and Diabetes Institute
▾Tap for detailsClick for full details — eligibility, all locations, contacts Vericiguat and Reverse Remodeling Indices in Heart Failure
RecruitingThe goal of this clinical trial is to investigate how vericiguat benefits adults with stable heart failure with reduced ejection fraction (HFrEF) who are already receiving guideline-directed medical therapy. The main questions are: * Does vericiguat improve right ventricular systolic function, measured by fractional area change (FAC)? * Does vericiguat favourably influence myocardial remodeling, fibrosis, angiogenesis, inflammation, metabolism, renal function, and hematologic balance? * Do genetic and oxidative stress profiles modify treatment response? Researchers will compare a group receiving vericiguat plus usual care with a group receiving usual care alone to assess structural, functional, and biomarker changes over 12 months. Participants will: * Have blood drawn at baseline and follow-up visits for biomarker, metabolomic, genetic, transcriptomic, and hematologic analyses, including platelet function testing * Perform oral glucose tolerance tests (OGTT) to assess insulin resistance * Undergo echocardiography, cardiac magnetic resonance imaging, and cardiac scintigraphy to evaluate heart structure, function, and perfusion * Attend follow-up visits at 1, 3, 6, and 12 months Open-label extension: After the 12-month randomized phase, participants originally assigned to usual care will be offered open-label vericiguat and followed for an additional 12 months. This exploratory extension will reassess study outcomes to evaluate the consistency and magnitude of response to vericiguat in the prior control cohort.
PhasePhase 4
TypeInterventional
Age18 Years
WhereIzola, Slovenia + 3 more
SponsorUniversity Medical Centre Ljubljana
▾Tap for detailsClick for full details — eligibility, all locations, contacts Physical Rehabilitation for Older Patients With Acute Heart Failure With Preserved Ejection Fraction
RecruitingThe REHAB-HFpEF trial will determine whether a novel physical rehabilitation intervention will improve the primary outcome of combined all-cause rehospitalizations and mortality and the secondary outcome of major mobility disability during 6-month follow-up in patients hospitalized for heart failure and preserved ejection fraction (HFpEF), which is nearly unique to older persons, and for which there are few treatment options.
PhaseNA
TypeInterventional
Age60 Years
WhereWinston-Salem, North Carolina, United States
SponsorWake Forest University Health Sciences
▾Tap for detailsClick for full details — eligibility, all locations, contacts Danish Pragmatic Randomized Trial to Evaluate the Effect of HeartLogic-Guided Management on Heart Failure Outcomes
NCT06099158 ·
Heart Failure RecruitingThe purpose of the study is to assess the impact of HeartLogic-guided management on clinical outcomes among patients implanted with an eligible cardiac device.
PhaseNA
TypeInterventional
Age18 Years
WhereHellerup, Capital Region, Denmark + 4 more
SponsorTor Biering-Sørensen
▾Tap for detailsClick for full details — eligibility, all locations, contacts New MRI Methods Applied to Heart Failure With Preserved Ejection Fraction (HFpEF)
NCT04600115 · MRI Scans
RecruitingThis study's main specific aims are; 1. To develop robust acquisition and reconstruction methods specifically for the study of microvascular cardiac remodeling with MRI which will include very innovative quantitative perfusion methods, as well as fibrosis quantification, longitudinal strain, and phase contrast imaging for flow. 2. Test the new methods for identifying the clinical task of characterizing HFpEF.
PhaseEARLY_Phase 1
TypeInterventional
Age18 Years
WhereSalt Lake City, Utah, United States
SponsorUniversity of Utah
▾Tap for detailsClick for full details — eligibility, all locations, contacts Predictors of Poor Prognosis in HFpEF
NCT06844032 · HFpEF
RecruitingPatients with HFpEF who have undergone meticulous clinical and instrumental evaluation (including diastolic exercise testing) between 2013 and 2020, will be followed up for at least 3 years.
Phase—
TypeObservational
Age40 Years
WhereMoscow, Russia
SponsorNational Medical Research Center for Cardiology, Ministry of Health of Russian Federation
▾Tap for detailsClick for full details — eligibility, all locations, contacts